Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DFI mRNA
- Development stage
- Preclinical
- Lead developer
- Broad Institute
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**DFI mRNA** is a preclinical, liver-targeted lipid-nanoparticle mRNA therapeutic comprising modified mRNAs encoding Delta-like ligand 1, Fms-like tyrosine kinase 3 ligand, and interleukin-7. Following transient hepatocyte expression, membrane-bound DLL1 and secreted FLT3-L and IL-7 promote Notch, FLT3, and IL-7 signaling to expand common lymphoid progenitors, improve thymic seeding and de novo thymopoiesis, and restore naïve T-cell output in aged mice. In reported murine studies, DFI mRNA enhanced vaccine-specific cellular and humoral immunity and improved antitumor activity, including responses to immune checkpoint inhibition, without observed autoimmune exacerbation. The program is an early preclinical approach for immunosenescence and age-associated impairment of vaccine and cancer-immunotherapy responses.
- Other names
- DFIDLL1 + FLT3-L + IL-7 mRNA
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)NOTCH (Neurogenic locus notch homolog protein 3)IL7R (Interleukin-7 Receptor)
Beyond the preview
Go deeper on DFI mRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DFI mRNA.